Omalizumab Treats Aspirin-Induced Asthma Complicated With Nasosinusitis and Otitis Media:Report of One Case.
10.3881/j.issn.1000-503X.15265
- Author:
Rui TANG
1
;
Shu-Bin LEI
2
;
Yi WANG
3
Author Information
1. Department of Allergy,Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease,National Clinical Research Center for Dermatologic and Immunologic Diseases,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
2. Eight-Year Program of Clinical Medicine,CAMS and PUMC,Beijing 100730,China.
3. Department of Otolaryngology and Head and Neck Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
asthma;
nasosinusitis;
omalizumab;
otitis media
- MeSH:
Humans;
Omalizumab/adverse effects*;
Asthma, Aspirin-Induced;
Asthma/drug therapy*;
Otitis Media/drug therapy*
- From:
Acta Academiae Medicinae Sinicae
2023;45(4):699-702
- CountryChina
- Language:Chinese
-
Abstract:
Omalizumab,as a biological agent targeting IgE,is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media,we discussed the value of omalizumab in the treatment of asthma and its complications,aiming to provide a reference for clinical practice.
